



Interplonal Application No PCI/EP 03/13514

A. CLASSIF IPC 7	A61K33/04 A61P31/14 A61K31/00)	
According to	International Palent Classification (IPC) or to both national classificat	ion and IPC	
B. TIELDS S			
Minimum doo IPC 7	cumentation searched (dassification system followed by classification of A61K A61P	n symbols)	
	on searched other than minimum documentation to the extent that su		ned
	ata base consulted during the international search (name of data bas ternal, EMBASE, CHEM ABS Data, BIOSI		
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category •	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.
х	WO 02/084294 A (AXXIMA PHARMACEUT; HERGET THOMAS (DE); COTTEN MATTH 24 October 2002 (2002-10-24) cited in the application the whole document page 5, line 8 - line 17 page 6, line 14 - line 17 page 7, line 25 - line 37 page 11, line 11 - line 22 page 12, line 28 - line 43		1-50
X Fur	ther documents are listed in the continuation of box C.	X Patent family members are listed in	annex.
Special c	ategories of cited documents:	BTI leter desument mittaked after the 1-to-	national filtre data
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the International filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but tater than the priority date claimed		The later document published after the International filing date or priority date and not in conflict with the application but died to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to hvolve an invention step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family	
Date of the actual completion of the International search 2 July 2004		Date of mailing of the international sear	1 4 0Z. 2004
Name and	i malling address of the ISA European Palent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,	Authorized officer Economou D	



Interctional Application No PCT/EP 03/13514

C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
x .	LOOK M P ET AL: "Interferon/antioxidant combination therapy for chronic hepatitis C-A controlled pilot trial" ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 43, no. 2, 1999, pages 113-122, XP002232553 ISSN: 0166-3542 the whole document abstract page 115, right-hand column, line 2 - line 3	1-50
X	DE 43 20 878 A (LESKOVAR PETER DR DR HABIL) 26 January 1995 (1995-01-26) column 40, line 61 - line 62	1,4,7,8,
X	EP 1 046 399 A (SCHERING CORP) 25 October 2000 (2000-10-25) page 2, line 5 - line 58 page 3, line 38 - page 4, line 5 page 4, line 22 page 5, line 12 - line 13 page 5, line 36 - line 52 page 5, line 55 - page 6, line 33 claims 2-4,8-14	1-41
X	WO 02/066022 A (WILLIAMS ANTHONY H; ARONEX PHARMACEUTICALS INC) 29 August 2002 (2002-08-29) cited in the application the whole document page 1, lines 3-7 page 3, line 19 - page 6, line 2 page 8, line 3 - line 6 examples 1,2 page 13, line 3 - line 14	1-3, 5-11, 13-29, 31-50
X	WO 97/03682 A (CIRD; FONTANA JOSEPH A (US)) 6 February 1997 (1997-02-06) page 19, line 24 - page 24, line 15 claims 14,15,17,21	1-3,5-8, 19,20
X	WO 97/13505 A (CIRD; REICHERT UWE (FR); SZONDY ZSUZSA (HU); FESUS LASZLO (HU)) 17 April 1997 (1997-04-17) page 7, line 19 - line 20 page 8, line 5 the whole document	1-3, 5-11, 13-29, 31-50
х	DE 36 10 531 A (MCNEILAB INC) 16 October 1986 (1986-10-16) claims 1-11 the whole document	1,7,8,19



Interactional Application No PCT/EP 03/13514

	·	PUI/EP US/	13514
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	R	elevant to dalm No.
X	WO 02/32413 A (LIM SOO JEONG; LOPEZ BERESTEIN GABRIEL (US); TARI ANA M (US); UNIV TE) 25 April 2002 (2002-04-25) page 11, line 1 - page 25, line 10 page 75, line 13 - line 22 page 78, line 4 - page 81, line 20 example 4		1-3,5-8, 19
X	US 2001/037032 A1 (STRELCHENOK OLEG) 1 November 2001 (2001-11-01) cited in the application the whole document		1-3,7,8, 19
X	DE 199 36 672 A (HERMES FABRIK PHARM PRAEPARATE) 15 February 2001 (2001-02-15)		1-3, 5-11, 13-29, 31-50
P,X	US 2003/180719 A1 (HERGET THOMAS ET AL) 25 September 2003 (2003-09-25)		1-50
	the whole document		
			-
]			
			·
1			
			1
			į
	•		
L			